Benlysta | search
Click here to view Benlysta news from 60+ newspapers.
Bookmark or Share- BENLYSTA. - Food and Drug AdministrationBENLYSTA (belimumab) is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Limitations of...
- Benlysta: Side effects, uses, cost, dosage, and more - Medical News TodayBenlysta is a brand-name drug that’s prescribed for a certain type of lupus and lupus nephritis. Benlysta contains the active drug belimumab. Benlysta is FDA-approved to treat: A type of...
- Benlysta: What you need to know | Lupus Foundation of AmericaBenlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020. Benlysta was approved to treat lupus in children in 2019 and lupus nephritis in children in 2022.
- Benlysta: Side Effects, Cost, Uses, and More - HealthlineWhat is Benlysta? If you have lupus, your doctor may recommend Benlysta for you. Specifically, Benlysta is used in adults and some children with one of the following conditions: systemic lupus...
- GSK announces US FDA approval of Benlysta (belimumab) for pediatric ...BENLYSTA, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. BENLYSTA does not bind B cells directly. By binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.
More
